Armata Pharmaceuticals takes $25 million secured loan from Innoviva

The loan

Armata Pharmaceuticals, Inc. entered into a credit and security agreement with Innoviva Strategic Opportunities LLC on May 12, 2026, according to an 8-K. The facility is a secured term loan of $25 million at an interest rate of 14.0% a year. It matures on January 11, 2029. Innoviva Strategic Opportunities LLC is a wholly owned subsidiary of Innoviva, Inc., which the filing describes as a principal shareholder of the company. The company announced the loan in a press release dated May 13, 2026, furnished as Exhibit 99.1 to the 8-K. The company's common stock is listed on NYSE American under the symbol ARMP. David House, senior vice president of finance and principal financial officer, signed the 8-K.

Repayment of the loan is guaranteed by the company's domestic subsidiaries. The loan is secured by substantially all of the assets of Armata and the subsidiary guarantors. The filing names no placement agent, financial advisor or counsel for the loan; the lender is Innoviva Strategic Opportunities LLC.

The agreement contains customary affirmative and negative covenants. These cover financial reporting and limits on indebtedness, liens, investments, collateral, distributions including dividends, and mergers, acquisitions and fundamental corporate changes. The events of default include payment defaults, breaches of the loan documents, certain losses or impairment of collateral, events that could reasonably be expected to have a material adverse effect, bankruptcy or insolvency, and a material deviation from the company's operating budget. The 8-K says the description is qualified by the full agreement, which is filed as Exhibit 10.1.

The business

Armata describes itself as a late clinical-stage biotechnology company developing bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company says it has completed three Phase 2 randomized, double-blind, placebo-controlled trials. It is advancing two candidates, AP-PA02 and AP-SA02, which target two different bacterial pathogens. It says they could treat chronic pulmonary disease complicated by bacterial infection, as well as acute systemic bacterial infection.

The company says it has improved its manufacturing process, which it describes as increasing phage titers and purity, and that it can now produce high-titer, high-purity phages with lot-to-lot consistency. It also says its phage platform is set up for commercial use. The 10-K describes phages as a potentially safer and effective alternative to antibiotics, and says the company is working toward randomized controlled trials. Armata's own description of phages as a safer alternative to broad-spectrum antibiotics is the company's position, not an independent finding.

The 10-K describes the earlier AP-PA02 work in cystic fibrosis as a Phase 1b/2a study of safety and tolerability, run with a $5.0 million award from the Cystic Fibrosis Foundation that the company received in full in 2024. It says bacterial levels in sputum "suggest improvement" against placebo after ten days of dosing, which is a hedged reading of a safety-focused study. The company reported what it called encouraging results in December 2024 from the Phase 2 Tailwind study in non-cystic fibrosis bronchiectasis, where the primary efficacy endpoint was a reduction in P. aeruginosa colony forming units in the lung. The 10-K says the company still intends to evaluate its phages in randomized controlled trials of safety and efficacy to support potential approval, so those trials are ahead.

Losses and cash

The company's 10-K reports a net loss of $173.8 million for 2025, against $18.9 million for 2024. Cash used in operations was $25.8 million in 2025, against $37.6 million in 2024. Year-end cash and cash equivalents were $9.3 million at the end of 2024. The 10-K was filed March 25, 2026.

The 8-K also furnished the company's results for the three months ended March 31, 2026, in the same press release that announced the loan.

The 8-K does not say how the company will use the $25 million. Cash used in operations fell from $37.6 million in 2024 to $25.8 million in 2025, but the net loss rose from $18.9 million to $173.8 million over the same period. The loan carries a 14.0% rate, is secured on substantially all assets, and comes from a lender that the filing describes as a principal shareholder. Its events of default also include a material deviation from the company's operating budget, a trigger that reaches beyond missed payments.

Report an error

Companies in this story

ARMPArmata Pharmaceuticals, Inc.AMEX · United StatesOpen the starter desk